CN103145968A - 叶酸偶联聚乙二醇单硬脂酸酯及其制备方法与应用 - Google Patents
叶酸偶联聚乙二醇单硬脂酸酯及其制备方法与应用 Download PDFInfo
- Publication number
- CN103145968A CN103145968A CN2012104835862A CN201210483586A CN103145968A CN 103145968 A CN103145968 A CN 103145968A CN 2012104835862 A CN2012104835862 A CN 2012104835862A CN 201210483586 A CN201210483586 A CN 201210483586A CN 103145968 A CN103145968 A CN 103145968A
- Authority
- CN
- China
- Prior art keywords
- polyethylene glycol
- folate
- folic acid
- glycol monostearate
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 title claims abstract description 96
- 239000011724 folic acid Substances 0.000 title claims abstract description 72
- 235000019152 folic acid Nutrition 0.000 title claims abstract description 71
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 title claims abstract description 59
- 239000002202 Polyethylene glycol Substances 0.000 title claims abstract description 59
- 229920001223 polyethylene glycol Polymers 0.000 title claims abstract description 59
- 229940014144 folate Drugs 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 38
- 229960000304 folic acid Drugs 0.000 claims abstract description 38
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims abstract description 33
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims abstract description 18
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims abstract description 14
- 238000000502 dialysis Methods 0.000 claims abstract description 12
- 238000003756 stirring Methods 0.000 claims abstract description 11
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract description 10
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000006227 byproduct Substances 0.000 claims abstract description 6
- 238000004108 freeze drying Methods 0.000 claims abstract description 6
- 238000010438 heat treatment Methods 0.000 claims abstract description 3
- 239000002502 liposome Substances 0.000 claims description 52
- 125000003929 folic acid group Chemical group 0.000 claims description 13
- HOGDNTQCSIKEEV-UHFFFAOYSA-N n'-hydroxybutanediamide Chemical compound NC(=O)CCC(=O)NO HOGDNTQCSIKEEV-UHFFFAOYSA-N 0.000 claims description 13
- 239000002105 nanoparticle Substances 0.000 claims description 11
- 229920000642 polymer Chemical group 0.000 claims description 11
- 239000002047 solid lipid nanoparticle Substances 0.000 claims description 11
- 239000012043 crude product Substances 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 230000014759 maintenance of location Effects 0.000 claims description 5
- 238000011049 filling Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 abstract description 20
- 230000008685 targeting Effects 0.000 abstract description 16
- 229940079593 drug Drugs 0.000 abstract description 10
- 238000012377 drug delivery Methods 0.000 abstract description 4
- 231100000419 toxicity Toxicity 0.000 abstract description 3
- 230000001988 toxicity Effects 0.000 abstract description 3
- 239000000047 product Substances 0.000 abstract 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 238000005303 weighing Methods 0.000 abstract 1
- 229960001756 oxaliplatin Drugs 0.000 description 39
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 39
- 206010028980 Neoplasm Diseases 0.000 description 22
- 230000000694 effects Effects 0.000 description 16
- 229940104914 oxaliplatin injection Drugs 0.000 description 11
- 241000699660 Mus musculus Species 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 238000011580 nude mouse model Methods 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 8
- 239000000969 carrier Substances 0.000 description 7
- 229940090044 injection Drugs 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 206010009944 Colon cancer Diseases 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000005909 tumor killing Effects 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 229940093181 glucose injection Drugs 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000002539 nanocarrier Substances 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940064302 folacin Drugs 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001033 granulometry Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- -1 polyoxyethylene Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210483586.2A CN103145968B (zh) | 2012-11-23 | 2012-11-23 | 叶酸偶联聚乙二醇单硬脂酸酯及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210483586.2A CN103145968B (zh) | 2012-11-23 | 2012-11-23 | 叶酸偶联聚乙二醇单硬脂酸酯及其制备方法与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103145968A true CN103145968A (zh) | 2013-06-12 |
CN103145968B CN103145968B (zh) | 2015-01-14 |
Family
ID=48544320
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210483586.2A Active CN103145968B (zh) | 2012-11-23 | 2012-11-23 | 叶酸偶联聚乙二醇单硬脂酸酯及其制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103145968B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104739766A (zh) * | 2013-12-26 | 2015-07-01 | 华东理工大学 | 一种纳米叶酸脂质体及其超临界二氧化碳制备方法 |
CN105434407A (zh) * | 2015-12-09 | 2016-03-30 | 中国药科大学 | 一种高生物利用度的姜黄素纳米脂质载体 |
CN107137377A (zh) * | 2017-03-29 | 2017-09-08 | 浙江大学 | 一种肿瘤干细胞靶向脂质纳米粒及制备方法与应用 |
US9890245B2 (en) | 2013-12-02 | 2018-02-13 | Jenkem Technology Co., Ltd. (Tianjin) | Stearic acid derivatives and oleic acid derivatives of multi-arm polyethylene glycol |
CN114965761A (zh) * | 2022-05-17 | 2022-08-30 | 深圳赛保尔生物药业有限公司 | 聚乙二醇化蛋白药物中n-羟基琥珀酰亚胺的检测方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101103985A (zh) * | 2006-07-14 | 2008-01-16 | 北京华安佛医药研究中心有限公司 | 叶酸滴丸及其制备方法 |
WO2008134071A1 (en) * | 2007-04-26 | 2008-11-06 | Theraquest Biosciences, Inc. | Multimodal abuse resistant extended release formulations |
US20090004281A1 (en) * | 2007-06-26 | 2009-01-01 | Biovail Laboratories International S.R.L. | Multiparticulate osmotic delivery system |
-
2012
- 2012-11-23 CN CN201210483586.2A patent/CN103145968B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101103985A (zh) * | 2006-07-14 | 2008-01-16 | 北京华安佛医药研究中心有限公司 | 叶酸滴丸及其制备方法 |
WO2008134071A1 (en) * | 2007-04-26 | 2008-11-06 | Theraquest Biosciences, Inc. | Multimodal abuse resistant extended release formulations |
US20090004281A1 (en) * | 2007-06-26 | 2009-01-01 | Biovail Laboratories International S.R.L. | Multiparticulate osmotic delivery system |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9890245B2 (en) | 2013-12-02 | 2018-02-13 | Jenkem Technology Co., Ltd. (Tianjin) | Stearic acid derivatives and oleic acid derivatives of multi-arm polyethylene glycol |
CN104739766A (zh) * | 2013-12-26 | 2015-07-01 | 华东理工大学 | 一种纳米叶酸脂质体及其超临界二氧化碳制备方法 |
CN104739766B (zh) * | 2013-12-26 | 2019-04-26 | 华东理工大学 | 一种纳米叶酸脂质体及其超临界二氧化碳制备方法 |
CN105434407A (zh) * | 2015-12-09 | 2016-03-30 | 中国药科大学 | 一种高生物利用度的姜黄素纳米脂质载体 |
CN105434407B (zh) * | 2015-12-09 | 2018-06-19 | 中国药科大学 | 一种高生物利用度的姜黄素纳米脂质载体 |
CN107137377A (zh) * | 2017-03-29 | 2017-09-08 | 浙江大学 | 一种肿瘤干细胞靶向脂质纳米粒及制备方法与应用 |
CN107137377B (zh) * | 2017-03-29 | 2019-10-11 | 浙江大学 | 一种肿瘤干细胞靶向脂质纳米粒及制备方法与应用 |
CN114965761A (zh) * | 2022-05-17 | 2022-08-30 | 深圳赛保尔生物药业有限公司 | 聚乙二醇化蛋白药物中n-羟基琥珀酰亚胺的检测方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103145968B (zh) | 2015-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yu et al. | Antitumor activity of a unique polymer that incorporates a fluorescent self-assembled metallacycle | |
Czapar et al. | Tobacco mosaic virus delivery of phenanthriplatin for cancer therapy | |
Xiong et al. | Doxorubicin-loaded carborane-conjugated polymeric nanoparticles as delivery system for combination cancer therapy | |
Eliezar et al. | In vivo evaluation of folate decorated cross-linked micelles for the delivery of platinum anticancer drugs | |
Sood et al. | Synthesis and characterization of AP5346, a novel polymer-linked diaminocyclohexyl platinum chemotherapeutic agent | |
CN101259284A (zh) | 一种基于树形聚合物肝靶向抗癌纳米前药系统、制备及用途 | |
Hu et al. | Core cross-linked polyphosphoester micelles with folate-targeted and acid-cleavable features for pH-triggered drug delivery | |
Du et al. | Intracellular tracking of drug release from pH-sensitive polymeric nanoparticles via FRET for synergistic chemo-photodynamic therapy | |
US9629923B2 (en) | Cisplatin complex and preparation method thereof | |
CN103342788B (zh) | 三嵌段聚阳离子、其制备方法及用途 | |
Huang et al. | Liver‐targeting doxorubicin‐conjugated polymeric prodrug with pH‐triggered drug release profile | |
CN103145968B (zh) | 叶酸偶联聚乙二醇单硬脂酸酯及其制备方法与应用 | |
CN103834002A (zh) | 基于聚乙二醇的酸敏感性阿霉素前药及其制备方法与应用 | |
CN102863557A (zh) | 乳糖酸修饰的脂肪酸-三甲基壳聚糖聚合物制备方法及应用 | |
Li et al. | Self-targeted polysaccharide prodrug suppresses orthotopic hepatoma | |
Lan et al. | Acetal-functionalized pillar [5] arene: a pH-responsive and versatile nanomaterial for the delivery of chemotherapeutic agents | |
Perche et al. | Hypoxia-responsive copolymer for siRNA delivery | |
CN111053911A (zh) | 还原响应型交联剂及其交联羟基药物分子的制备及应用 | |
CN104856950A (zh) | 一种紫杉醇胶束载药系统及其制备方法 | |
CN108524529B (zh) | 基于两性离子及叶酸靶向的酸敏感性阿霉素前药及其制备方法与应用 | |
CN102988293B (zh) | 一种奥沙利铂叶酸靶向脂质体及其应用 | |
Yang et al. | Study on enhanced lymphatic exposure of polyamidoamin-alkali blue dendrimer for paclitaxel delivery and influence of the osmotic pressure on the lymphatic targeting | |
CN102600190B (zh) | 阿霉素的脂质药物组合物 | |
Yang et al. | Evaluation of a tumor-targeting oligosaccharide nanosystem in BNCT on an orthotopic hepatocellular carcinoma model | |
CN102604083B (zh) | 聚合物修饰的脂质材料及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240402 Address after: Buildings 1-4, North Building 3, Medical Device Technology Industrial Park, No.1 Yunhai Road, Lihai Street, Yuecheng District, Shaoxing City, Zhejiang Province, 312000 Patentee after: Zhejiang Zhida Pharmaceutical Co.,Ltd. Country or region after: China Address before: Hangzhou City, Zhejiang province 310036 Xiasha Higher Education Park forest Street No. 16 Patentee before: Hangzhou Normal University Country or region before: China |